65,437 trials
Estrogen Receptor and/or Progesterone Receptor Positive · HER2/Neu Negative · Stage IV Breast Cancer AJCC v6 and v7
Primary: Number of Participants With Grade 2 and Above Toxicities Attributed to Ribociclib — 2 Participants
Chronic Non-malignant Pain
Primary: Pain Impact Assessed Using the 4-Item Version of Brief Pain Inventory-Short Form ("PEGS") — 6.485; 6.645; 5.486; 6.210 score on a scale
Thrombosis
Primary: Composite of Adjudicated Major or Clinically Relevant Non-Major (CRNM) Bleeding Events — 1; 3 Participants
Depression · Problematic Alcohol Use
Primary: The Integrated Measure of Implementation Context and Outcomes as a Change Over Time in Low and Middle Income Countries Consumer Instrument — 2.76; 3.22; 3.21; 2.91 score…
Childhood Germ Cell Tumor · Ovarian Cancer · Teratoma
Primary: Overall Survival (OS) — 86; 56 percentage of participants
Oncology Patients Receiving Chemotherapy
Primary: Number of Hypersensitivity Reactions to Treatment With an Anti-CD20 Antibody or Paclitaxel — 2; 3 Participants
Leukemia · Lymphoma · Small Intestine Cancer
Primary: Maximum Tolerated Dose — 20 mg/m2 of clofarabine
Depression
Primary: Change in Functional Corticostriatal Connectivity — 0.10; 0.04; 0.07; 0.00 Z-score
Bioequivalence
Primary: PK Parameters — 283; 341; 189 ng*h/mL
Acute Respiratory Distress Syndrome · Acute Respiratory Failure
Primary: Feasibility — 14 Participants
Chronic Kidney Disease
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 6; 2 Participants
Amyloid-beta
Primary: Difference in Amyloid-beta (Abeta) Concentration in the CSF (Cerebral Spinal Fluid) of Individuals With Poor Sleep Efficiency Compared to Those With Good Sleep…
Tinnitus
Primary: Tinnitus Functional Index — 57.7; 39.6 score on a scale
Arterial Stiffness · Inflammation
Primary: Change From Baseline in Serum Levels of Lycopene at 4 Weeks — 7.30; 3.09 uM
Healthy Volunteers
Primary: Anxiety-potentiated Startle — 6.032164105; 2.420193836; 3.412441384; 4.467812115 T-scores